With ambitious routing and an adaptable show, the Australian trio is successfully straddling the rock and dance worlds. By Katie Bain “Let’s make this Saturday night a special one,” Rüfüs Du Sol’s ...

Zaria turned on her now former partner Sol Ruca during a memorable angle on this week's episode of WWE NXT. The turn happened during introductions for Sol's NXT Women's Title bout vs. Jacy Jayne. The ...

We may receive a portion of sales if you purchase a product through a link in this article. Sol de Janeiro’s scent family is basically its own category at this point. They’re warm, instantly ...

Sol Ruca is fresh off a star-making performance at Royal Rumble 2026 in Saudi Arabia, where she impressed a legion of WWE fans with her in-ring athleticism and off-the-charts charisma. However, all's ...

Solana price has climbed about 5.5% over the past seven days, holding near the $85 level. This rebound followed a sharp decline earlier this month. But beneath this recovery, a major supply shift is ...

A new framework allows institutions to borrow against staked SOL while the assets remain in qualified custody, as US lawmakers debate DeFi oversight. Anchorage Digital has partnered with Kamino and ...

Former NXT Women's Champion Sol Ruca is one step closer to ruling the NXT women's division. On the latest episode of the brand, Ruca pinned Kendall Grey to be the No. 1 contender for the NXT Women's ...

WWE superstar Sol Ruca continues to prove that she's one of the hottest names in the industry right now. Wrestling fans around the world got a long look at Ruca during this year's Royal Rumble in ...

Though we're one week removed from this year's Royal Rumble PLE, Sol Ruca's performance in the Women's Rumble match still lives rent free in most fans' minds. Arguably the MVP of that contest, the ...

Solana network activity has spiked to record levels. The market could bottom at $97 as RSI and sentiment readings have reached extremes. A bearish target for SOL in case of a breakout could be set at ...

Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risked ...

After playing well over 200 new releases this year, I am officially closing the book on 2025. My year-end list is published, as is Polygon’s, and I am at peace with the final results, even knowing ...